InvestSMART

Algorae Pharmaceuticals Limited (ASX:1AI)

ALERT: Price-sensitive ASX Announcement for 1AI
Current share price for 1AI : $0.013 0.001 (4.17%)+
Announcement
Release
28 Apr 2026 8:35AM
Price at Release
$0.012
Full Release
download
Summary
Algorae Pharmaceuticals Limited has entered into an exclusive commercial and licensing agreement with Zydus Lifesciences Ltd for the Australian and New Zealand markets. This agreement covers the commercialisation of 10 pharmaceutical products, including injectable, oral, and specialty medicines. Algorae's strategy is to build a reliable, compliant pharmaceutical portfolio for these markets, supported by Zydus's global manufacturing capabilities. The collaboration is aimed at expanding access to high-quality medicines in regulated markets, with product prioritisation being jointly managed to ensure regulatory compliance and market readiness. Algorae's commercial platform will be strengthened through this partnership, which aligns with its long-term strategy for sustainable growth in highly regulated environments.
Key Points
  • Algorae and Zydus enter exclusive commercial agreement
  • Covers injectable, oral, and specialty medicines
  • Target markets are Australia and New Zealand
  • Supports strategy for a compliant pharmaceutical portfolio
  • Collaboration leverages Zydus's global manufacturing capabilities
  • Focus on regulatory compliance and market access
  • Strengthens Algorae’s commercial platform
  • Aims to expand access to quality medicines in regulated markets
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.